Peptide Schedule
Apelin-1212 residuesRPRLSHKGPMPFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Apelin-12
Benefits
About Apelin-12
Apelin-12 is the shortest biologically active fragment of the 77-amino-acid preproapelin peptide, cleaved from the C-terminal region to yield the sequence RPRLSHKGPMPF (CAS 229961-08-4). It acts as an endogenous ligand for the APJ receptor (also called APLNR), an orphan G protein-coupled receptor first identified in 1993 and subsequently deorphanized when apelin was discovered in 1998 from bovine stomach extracts. Among the apelin isoforms (apelin-36, -17, -13, and -12), apelin-12 shows the strongest blood pressure-lowering effect in normotensive rats. In anesthetized rats, a single intravenous dose of 10 nmol/kg reduced mean arterial pressure by 26±5 mmHg — more than double the reduction seen with apelin-13 (11±4 mmHg) and five times that of apelin-36 (5±4 mmHg). This depressor response was completely abolished by co-administration of a nitric oxide synthase inhibitor, confirming an NO-dependent mechanism. At the cellular level, apelin-12 binding to APJ on vascular endothelial cells activates the PI3K/Akt cascade, which phosphorylates endothelial nitric oxide synthase (eNOS) at Ser1177. The resulting NO production activates soluble guanylyl cyclase in smooth muscle cells, increasing cyclic GMP and inducing vascular relaxation. APJ couples primarily through Gi/o and Gq alpha subunits, activating downstream ERK1/2, p70S6K, and PKC signaling pathways that promote cardiomyocyte survival and angiogenesis. In cardiac ischemia-reperfusion (I/R) injury models, apelin administration reduces infarct size, suppresses lactate dehydrogenase release, and limits cardiomyocyte apoptosis. Apelin-knockout mice show markedly worsened cardiac fibrosis and pathological remodeling when challenged with angiotensin II, indicating the apelin system acts as an endogenous counter-regulatory brake on the renin-angiotensin-aldosterone system (RAAS). Apelin also inhibits angiotensin II-induced atrial fibrosis through the TGF-beta1/Smad2/alpha-SMA pathway, reducing vulnerability to atrial fibrillation in animal models. The apelin/APJ system has attracted drug development interest, with the small-molecule APJ agonist AMG 986 (Amgen) completing a first-in-human Phase 1b trial in healthy subjects and heart failure patients (NCT03276728). AMG 986 was tolerated at doses up to 650 mg/day, though clinically meaningful pharmacodynamic effects in heart failure patients were not observed in the short-term study. Native apelin-12 itself remains limited to preclinical investigation due to its extremely short plasma half-life (~5 minutes), driven by rapid cleavage by ACE2 (angiotensin-converting enzyme 2) at the C-terminal Pro-Phe bond and by neprilysin (neutral endopeptidase 24.11). All dosing information is extrapolated from animal studies. No human clinical trials have tested apelin-12 peptide directly. This compound should be considered strictly experimental.
Who Should Consider Apelin-12
- Researchers studying the apelin/APJ signaling axis in cardiovascular disease models
- Scientists investigating endogenous counter-regulatory peptides to the RAAS system
- Individuals exploring experimental cardioprotective peptides under physician supervision
- Researchers studying NO-dependent vasodilation pathways and blood pressure regulation
- Those investigating anti-fibrotic strategies for cardiac remodeling prevention
How Apelin-12 Works
Apelin-12 binds the APJ receptor (APLNR), a class A G protein-coupled receptor expressed on vascular endothelial cells, cardiomyocytes, and smooth muscle cells. APJ couples through Gi/o and Gq alpha subunits, initiating multiple downstream signaling cascades. In the vasculature, the primary pathway is PI3K → Akt → eNOS phosphorylation (Ser1177) → NO release. Nitric oxide diffuses to adjacent smooth muscle cells, activating soluble guanylyl cyclase to increase cyclic GMP, which relaxes vascular smooth muscle and lowers blood pressure. This NO-dependent mechanism was confirmed when NOS inhibitors completely blocked the apelin-12 depressor response in rats. In cardiomyocytes, APJ activation triggers ERK1/2 phosphorylation and p70S6K signaling through PKC, promoting cell survival and inhibiting apoptosis. Apelin-12 blocks mitochondrial cytochrome c release and caspase activation during ischemic stress. The apelin/APJ axis also directly antagonizes angiotensin II signaling — APJ can hetero-dimerize with AT1 receptors, and apelin stimulation shifts the ACE/ACE2 balance toward ACE2 activity, favoring cardioprotective Ang(1-7) production over pathological Ang II signaling. Apelin-12 also inhibits fibrosis by suppressing the TGF-beta1/Smad2/alpha-SMA pathway, reducing collagen deposition and myofibroblast differentiation in atrial and ventricular tissue. This anti-fibrotic action contributes to preserved cardiac conduction and reduced arrhythmia vulnerability in preclinical models.
What to Expect
In animal models, intravenous apelin-12 produces an immediate blood pressure reduction peaking within minutes. The 26 mmHg mean arterial pressure drop in rats occurred rapidly after injection and was transient due to the ~5-minute half-life. Any perceived hemodynamic effect in humans would be expected in this acute window.
No established human timeline exists. In repeated-dose animal studies, daily administration maintained cardioprotective signaling. Theoretical subcutaneous dosing would produce brief daily peaks of APJ activation. Measurable biomarker changes (e.g., NO metabolites, blood pressure trends) might be detectable with daily dosing in this timeframe.
In animal I/R injury models, apelin treatment over 2-4 weeks reduced cardiac fibrosis markers and improved ejection fraction measurements. Anti-fibrotic effects via TGF-beta1/Smad2 pathway suppression were apparent in this timeframe in rodent studies.
Long-term data comes from apelin-knockout rescue experiments and chronic infusion studies in rodents. Sustained APJ activation over weeks to months improved cardiac remodeling outcomes. No long-term human data exists for native apelin-12 peptide. The AMG 986 small-molecule APJ agonist was tested for up to 14 days in humans without safety signals.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 150mcg | Daily |
| Aggressive | 300mcg | Daily |
Note: Apelin-12 is an endogenous 12-amino-acid peptide (sequence: RPRLSHKGPMPF) and the shortest active isoform of the apelin family. It is the natural ligand of the APJ receptor (APLNR), a class A GPCR expressed widely in cardiovascular tissue. All existing dosing data is derived from animal models — no human dosing protocols exist. The very short plasma half-life (~5 minutes) is a primary limitation for therapeutic use. Preclinical research compound only.
How to Inject Apelin-12
Subcutaneous: inject into abdominal fat tissue once daily, rotating injection sites. Reconstitute lyophilized powder with bacteriostatic water — inject slowly along the vial wall to preserve peptide integrity. Due to the very short plasma half-life (~5 minutes), effects are transient after a single dose. Some researchers use split dosing (2-3 times daily) to extend the window of activity, though this approach is entirely unvalidated in humans. Intravenous: used in research settings only, typically as a slow infusion to extend exposure time. Start at the lowest dose tier and monitor blood pressure response before escalating. Avoid dosing within 2 hours of other antihypertensive compounds. This is a preclinical research compound — all human dosing is extrapolated from animal pharmacology data.
Cycling Protocol
No established human cycling protocols exist. The 4-on/2-off recommendation is precautionary. The extremely short half-life (~5 minutes) means systemic accumulation is unlikely, but receptor desensitization with repeated daily dosing is a theoretical concern. APJ receptor internalization occurs rapidly after agonist binding, and repeated stimulation may downregulate surface receptor expression. Discontinue if any adverse effects such as dizziness, lightheadedness, or symptomatic hypotension occur.
Pharmacokinetics
Source: Native apelin peptides have an extremely short plasma half-life of approximately 5 minutes in circulation. ACE2 is the principal endopeptidase responsible for apelin inactivation, cleaving the C-terminal Pro-Phe bond. Neprilysin (NEP 24.11) also hydrolyzes apelin peptide bonds. Tatemoto et al. (2001) demonstrated the transient hemodynamic response consistent with rapid clearance. Modified apelin analogues with lipidation can extend half-life to ~29 hours in rat plasma.
Loading the interactive decay curve.
Side Effects
No human safety data exists for apelin-12. All information comes from animal studies and early human trials with related APJ agonists. The primary expected effect is hypotension due to NO-mediated vasodilation — this is dose-dependent and was the main observed pharmacodynamic effect across all apelin studies. In rat models, the depressor effect was transient due to the short half-life. Theoretical concerns include: excessive blood pressure reduction in already hypotensive individuals, potential fluid retention effects (apelin opposes vasopressin-mediated water reabsorption in the kidney, creating unpredictable fluid balance changes), and unknown immunogenic risk with repeated exogenous administration. The AMG 986 Phase 1b trial in humans (a small-molecule APJ agonist, not native apelin-12) showed an acceptable safety profile up to 650 mg/day with no clinically significant dose-related safety findings. Long-term safety of native apelin-12 peptide in humans is completely unknown.
Contraindications
- Hypotension or orthostatic hypotension — apelin-12 is a potent vasodilator and could worsen low blood pressure
- Concurrent use of multiple antihypertensive medications — additive hypotensive risk with no interaction data
- Pregnancy or breastfeeding — no reproductive toxicology data exists for exogenous apelin-12
- Active hemorrhage or conditions with compromised hemodynamic stability
- Known hypersensitivity to apelin peptides or related compounds
- Severe renal impairment — apelin interacts with vasopressin-mediated water balance in the kidney; effects on fluid handling in renal failure are unknown
Drug Interactions
- ACE inhibitors (enalapril, lisinopril) — apelin-12 is degraded by ACE2; ACE inhibitors may shift ACE/ACE2 balance and alter apelin metabolism unpredictably
- ARBs (losartan, valsartan) — APJ hetero-dimerizes with AT1 receptors; blocking AT1 while stimulating APJ has unstudied combined effects
- Beta-blockers — additive blood pressure lowering when combined with apelin-mediated vasodilation
- Calcium channel blockers (amlodipine, diltiazem) — additive hypotensive effects; no interaction data available
- Neprilysin inhibitors (sacubitril) — neprilysin degrades apelin; inhibition could prolong apelin-12 half-life and amplify effects
- Vasopressin or desmopressin — apelin opposes vasopressin action at the V2 receptor in renal collecting ducts; concurrent use may produce unpredictable water balance effects
- Other vasoactive peptides (BPC-157, SS-31, MOTS-c) — no combination data available; theoretical additive cardiovascular effects
Storage & Stability
Molecular Profile
Related Peptides
References
- The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism (Tatemoto et al., 2001)PubMed 11384769
- Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure (Japp et al., 2010)PubMed 20385929
- Vascular effects of apelin: mechanisms and therapeutic potential (Mughal & O'Rourke, 2018)PubMed 29807055
- Apelin inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation via TGF-beta1/Smad2/alpha-SMA pathway (Lv et al., 2020)PubMed
- Loss of apelin augments angiotensin II-induced cardiac dysfunction and pathological remodeling (Sato et al., 2019)PubMed 30634574
- Cardioprotective effects of apelin in myocardial ischemia/reperfusion injury: a systematic review and meta-analysis (2025)Review
- A first-in-human study of AMG 986, a novel apelin receptor agonist, in healthy subjects and heart failure patients (Hellawell et al., 2022)Clinical Trial
- The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR (Chapman et al., 2014)Review